NZ333813A - Pharmaceutical composition containing a 5HT2C antagonist and a D2 antagonist - Google Patents

Pharmaceutical composition containing a 5HT2C antagonist and a D2 antagonist

Info

Publication number
NZ333813A
NZ333813A NZ333813A NZ33381397A NZ333813A NZ 333813 A NZ333813 A NZ 333813A NZ 333813 A NZ333813 A NZ 333813A NZ 33381397 A NZ33381397 A NZ 33381397A NZ 333813 A NZ333813 A NZ 333813A
Authority
NZ
New Zealand
Prior art keywords
antagonist
pharmaceutical composition
5ht2c
composition containing
compound
Prior art date
Application number
NZ333813A
Other languages
English (en)
Inventor
Thomas Paul Blackburn
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NZ333813A publication Critical patent/NZ333813A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ333813A 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5HT2C antagonist and a D2 antagonist NZ333813A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9615767.2A GB9615767D0 (en) 1996-07-26 1996-07-26 Novel treatment
PCT/EP1997/004159 WO1998004289A2 (en) 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist

Publications (1)

Publication Number Publication Date
NZ333813A true NZ333813A (en) 2000-07-28

Family

ID=10797573

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ333813A NZ333813A (en) 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5HT2C antagonist and a D2 antagonist

Country Status (19)

Country Link
EP (1) EP0936924A2 (hu)
JP (1) JP2000516924A (hu)
KR (1) KR20000029564A (hu)
CN (1) CN1230894A (hu)
AR (1) AR008083A1 (hu)
AU (1) AU725817B2 (hu)
BR (1) BR9710568A (hu)
CA (1) CA2261813A1 (hu)
CO (1) CO5031292A1 (hu)
CZ (1) CZ23799A3 (hu)
GB (1) GB9615767D0 (hu)
HU (1) HUP9903619A3 (hu)
IL (1) IL128219A0 (hu)
NO (1) NO990322L (hu)
NZ (1) NZ333813A (hu)
PL (1) PL331426A1 (hu)
TR (1) TR199900140T2 (hu)
WO (1) WO1998004289A2 (hu)
ZA (1) ZA976593B (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612883D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
WO2000030649A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. Pharmaceutical compositions containing olanzapine-n-oxide
US6348455B1 (en) 1998-11-23 2002-02-19 Sepracor Inc. Desmetylolanzapine compositions and methods
JP2002530339A (ja) 1998-11-23 2002-09-17 セプラコール, インク. 2−ヒドロキシメチルオランザピン組成物及び方法
AU3757500A (en) 1999-03-18 2000-10-04 Childrens Hospital Research Foundation A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications
WO2000071106A2 (en) * 1999-05-19 2000-11-30 Astrazeneca Ab Method of treating weight gain
WO2005013969A1 (en) * 2003-07-15 2005-02-17 Janssen Pharmaceutica N.V. Antipsychotic agent with socializing properties

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500998D0 (sv) * 1995-03-19 1995-03-19 Haakan Wilhelm Wikstroem New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics

Also Published As

Publication number Publication date
ZA976593B (en) 1999-01-25
GB9615767D0 (en) 1996-09-04
AU4297297A (en) 1998-02-20
WO1998004289A3 (en) 1998-03-19
CA2261813A1 (en) 1998-02-05
BR9710568A (pt) 1999-08-17
KR20000029564A (ko) 2000-05-25
NO990322L (no) 1999-03-24
AU725817B2 (en) 2000-10-19
IL128219A0 (en) 1999-11-30
HUP9903619A2 (hu) 2000-10-28
PL331426A1 (en) 1999-07-19
CZ23799A3 (cs) 1999-06-16
WO1998004289A2 (en) 1998-02-05
CO5031292A1 (es) 2001-04-27
NO990322D0 (no) 1999-01-25
AR008083A1 (es) 1999-12-09
EP0936924A2 (en) 1999-08-25
JP2000516924A (ja) 2000-12-19
HUP9903619A3 (en) 2001-03-28
CN1230894A (zh) 1999-10-06
TR199900140T2 (xx) 1999-03-22

Similar Documents

Publication Publication Date Title
HUP9601419A2 (en) Synergetic pharmaceutical compositions for treating parkinson-disease
HU9602932D0 (en) Substituted imidazolidine-2,4-dion compounds as pharmaceutical agent
HUP0004693A3 (en) Oxo-substituted compounds inhibiting parp activity, pharmaceutical compositions containing them and process for preparation the compounds
HUP0101627A3 (en) Pharmaceutical compositions for treating neuropsychiatric disorders
NZ513889A (en) Kappa agonist compounds, pharmaceutical formulations and methods of prevention and treatment of pruritus therewith
ZA988012B (en) Amino-substituted compounds methods and compositions for inhibiting parp activity
AU9298098A (en) Amino-substituted compounds, methods, and compositions for inhibiting parp activity
HU9600765D0 (en) Use of a cgrp antagonist for treating skin redness of neurogenic origin, and compositions containing these compounds
IL127244A0 (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
BG102872A (en) 6-phenylpyridyl-3-amine derivatives
HUP0103344A3 (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp), process for their preparation and pharmaceutical compositions containing them
IL117079A (en) Pharmaceutical compositions containing 2-phenyl-2-aroyl-benzothiophenes for inhibiting cell-cell adhesion
ZA9610543B (en) Compounds and compositions for reducing blood glucose and/or inhibiting the activity of CGRP.
PL330752A1 (en) Pharmaceutical agent for treating urinary incontinence
HK1003436A1 (en) Novel benzimidazole derivatives having cgmp-phosphodisterase inhibiting activity
AU9298198A (en) Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
ZA9811629B (en) The use of MMP inhibitors for the treatment of ocular angiogenesis.
HUT73854A (en) Antipsychotic pharmaceutical compositions containing azabicyclo-thiadiazolo- or azabicyclo-oxadiazolo-derivatives
NZ333813A (en) Pharmaceutical composition containing a 5HT2C antagonist and a D2 antagonist
HU9801924D0 (en) Pharmaceutica composition for treating heart- and vascular troubles containing sodium-hydrogen-change-inhibitors
PL312908A1 (en) Drugs for treating aids and/or hiv infections, containing composition consisting of quinoxalin and protease inhibitors
IL132520A0 (en) A pharmaceutical composition for treating skin disorders containing a protein kinase c inhibitor
IL136867A0 (en) Triazine compounds for treatment of cns disorders
GB9611614D0 (en) Process for inhibiting the effect of flourescent whitening agents
IL117970A (en) Pharmaceutical compositions containing olanzapine for treating nicotine withdrawal

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)